Intensive Adjuvant Therapy for TNBC with BRCA Gene Mutation

Inclusion Criteria: * ECOG score 0-1 * TNBC * BRCA1/2 mutation * No distant metastases assessed by imaging after surgical treatment * Breast cancer that is non-pCR after neoadjuvant therapy, or postoperative pathology suggestive of ≥pT2, or ≥pN1 * Have completed postoperative adjuvant chemotherapy and/or radiotherapy * No major organ dysfunction Exclusion Criteria: * Patients who are unable to take oral medication, or who refuse this medication regimen * Already enrolled in another study, or less than or equal to 4 weeks from discontinuation of another medication * Presence of severe dysfunction of vital organs * Patients with other malignancies (with the exception of cured non-melanoma skin cancers, carcinoma in situ of the cervix and other tumours that have been cured for at least 5 years) * Acute infectious disease or active chronic infectious disease * History of uncontrolled epilepsy, central nervous system disease or mental disorder